 |
Prospector
Profile
07.1633
|
| |
| Carrington Laboratories, Inc. |
NAICS |
541710 |
| 2001 Walnut Hill Lane
Irving, TX 75038 |
Description |
Biotechnology |
| (972) 518-1300 |
Employees |
260 |
| http://www.carringtonlabs.com/ |
Revenue |
(mil) |
27.4060 |
| |
Income |
(mil) |
-7.6070 |
| |
Assets |
(mil) |
13.9980 |
| |
Liability |
(mil) |
9.8060 |
| |
(for the year ended 2006-12-31) |
| |
|
Category:
Loss/Deficit
|
| |
|
Event:
Carrington Laboratories, Inc. reported a net loss of $2.2 million on total revenues of $6.5 million for the third quarter ended Sept. 30, 2007, compared with a net loss of $1.8 million on total revenues of $6.7 million for the same period in 2006. Interest expense, net of interest income, during the quarter ended Sept. 30, 2007, increased $666,000 to $932,000, as compared to $266,000 for the quarter ended Sept. 30, 2006. At Sept. 30, 2007, the company's consolidated financial statements showed $17.3 million in total assets, $16.5 million in total liabilities, and $840,000 in total shareholders' equity.
|
| |
|
Intellectual Property:
The Company attempts to protect proprietary rights by filing U.S. and foreign patent applications related to its proprietary technology, inventions and improvements that are important to the development of the business. The Company intends to file additional patent applications relating to technologies, improvements to technologies and specific products it may develop. It also relies on trade secrets to protect technology, especially where patent protection is not believed to be appropriate or obtainable. The Company protects proprietary technology and processes, in part, by confidentiality agreements with employees, consultants and certain contractors. The Company's trademarks include Manapol®, Carrisyn®, Carrasyn®, CarraGauze®, Carrington®, AloeCeuticals®, CaraKlenz®, DelSite and design™, GelVac™, GelSite®, Salicept®, OraPatch®, and Brace-Eez®. [SEC Filing 10-K 04-02-07]
|
| |
|
Description:
The Company operates as a research-based biopharmaceutical, medical device, raw materials, and nutraceutical company.
|
| |
|
Officers:
Carlton E. Turner (Pres., CEO & Dir.); Robert W. Schnitzius (VP & CFO); R. Dale Bowerman (Dir.); George DeMott (Dir.); Alex McPherson (Dir.); Thomas J. Marquez (Dir.); Edwin Meese, III (Dir.)
|
| |
|
Auditor:
Ernst & Young LLP
|
| |
|
Securities:
Common Stock-Symbol CARN.OB; OTC BB;
10,951,103 common shares outstanding as of November 8, 2007.
|
| |
| |
| |
| return to main page |
|
|
